
Clearside Biomedical CLSD
Quarterly report 2025-Q3
added 11-14-2025
Clearside Biomedical Total Current Liabilities 2011-2026 | CLSD
Annual Total Current Liabilities Clearside Biomedical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.81 M | 5.78 M | 4.64 M | 9.94 M | 10.9 M | 10.5 M | 13.5 M | 5.41 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.5 M | 4.64 M | 8.44 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
54.1 M | - | - | $ 1.01 B | ||
|
Adagene
ADAG
|
38.2 M | $ 1.65 | 7.91 % | $ 92.9 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
195 M | $ 66.05 | 2.3 % | $ 8.83 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.52 | -16.3 % | $ 388 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Biogen
BIIB
|
5.53 B | $ 184.48 | -1.67 % | $ 26.9 B | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.05 M | $ 4.25 | 1.67 % | $ 9.25 B | ||
|
BeiGene, Ltd.
BGNE
|
2.21 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | ||
|
Bristol-Myers Squibb Company
BMY
|
23.8 B | $ 55.71 | -0.28 % | $ 113 B | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Codiak BioSciences
CDAK
|
27.2 M | - | -55.98 % | $ 2.15 M | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Cerevel Therapeutics Holdings
CERE
|
92.2 M | - | - | $ 7.29 B | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Zai Lab Limited
ZLAB
|
299 M | $ 18.37 | -0.97 % | $ 18.2 B | ||
|
Coherus BioSciences
CHRS
|
332 M | $ 1.61 | -5.03 % | $ 152 M | ||
|
Catalyst Biosciences
CBIO
|
20 M | $ 10.84 | 0.46 % | $ 714 M | ||
|
Caladrius Biosciences
CLBS
|
5.61 M | - | -16.75 % | $ 25.8 M | ||
|
Celldex Therapeutics
CLDX
|
39.5 M | $ 25.59 | -6.54 % | $ 1.65 M | ||
|
Chimerix
CMRX
|
18.4 M | - | - | $ 756 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
72.8 M | - | -15.15 % | $ 60.3 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
141 M | $ 37.35 | -0.4 % | $ 3.86 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
121 M | $ 23.18 | 2.02 % | $ 2.75 B | ||
|
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
59.7 M | $ 55.11 | 3.49 % | $ 4.45 B | ||
|
CRISPR Therapeutics AG
CRSP
|
87.8 M | $ 55.17 | 2.47 % | $ 4.65 B | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Zentalis Pharmaceuticals
ZNTL
|
69.4 M | $ 3.53 | -5.75 % | $ 231 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
174 M | $ 29.43 | 6.09 % | $ 1.43 B |